Benzodiazepine Drugs is anticipated to have CAGR of ~2.6% over 2019-2028. Benzodiazepines are psychoactive drugs which are used to treat insomnia, anxiety, seizures, and also alcohol withdrawal. There are various factors such as exposure to stressful lifestyle, the key reasons for mental disturbance, includes busy lifestyle that creates anxiety, and panic disorder conditions. The surge in prevalence of seizures, anxiety, insomnia, and surge in concern among people about preventive measures regarding stress-related conditions would help the industry to gain maximum revenue shares. The rise in adoption of generic drugs and comparatively increased prescription for benzodiazepines, as compared to the other drugs are anticipated to show lucrative growth in the coming years.

Top Driver: Increase In Prevalence Of diseases to boost the industry

Benzodiazepine Drugs is projected to grow with the increase in the prevalence of the diseases is anticipated to boost in the industry in the forecast period. The growth in the population of the individuals who are experiencing seizures, anxiety, and insomnia are expected to help the industry grow significantly in the coming years. According to the Anxiety and Depression Association Of America, Anxiety disorders are the most common mental illness in the U.S., affecting 40 million adults in the United States age 18 and older, or 18.1% of the population every year. Furthermore, Anxiety disorders are highly treatable, yet only 36.9% of those suffering receive treatment. This awareness regarding the growth in such disorders would help the industry to flourish.

Alprazolam to Make Crucial Contribution to Growth of Global Benzodiazepine Drugs Market

Among product segments of the global Benzodiazepine Drugs market, Alprazolam segment is anticipated to gain maximum revenue shares in the coming years. Owing to the advantages posed by the drug than any other drug classification, this is expected to help the industry grow in the forecast period. The key aspect that is considered to help the Alprazolam segment to gain highest CAGR also, is due to the wider range of applications that are attributed by the drug. Furthermore, the growth in number of prescriptions and the reliability of the doctors and the physicians on the efficacy of the drug would help the market to show a lucrative growth in the near future.

  Surge in the patient population to Benefit North American Market

North America is experiencing highest revenue growth than any other country and is expected to flourish further in the coming years. This is due to the increase in the density of the key players in the region. Furthermore the growth in the investment of the government and other public-private organizations to widen the range of the drug applications is expected to help the industry grow at a lucrative rate in the next few years.  The surge in the prevalence of the anxiety patients and the related conditions in the North American region would boost the industry in the coming years. In Asia Pacific region, the growth in the healthcare expenditure in the region would help the industry show growth significantly during the forecast period.

Due to outbreak of COVID-19 the growth of the patient population grew awareness regarding the spreading rate of the disease. This led the government to enforce lockout situation across various region and hence the industries had experienced negative growth in the forecast period. However, the awareness to have better quality of life is anticipated to help the industry boost in the coming years.

Players to Focus on Benzodiazepine Drugs

The global Benzodiazepine Drugs market leaders include F.Hoffmann-La Roche Ltd., Pfizer Inc., Bausch Health Companies, Inc., Mylan, N.V., H.Lundbeck A/S, Amneal Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Apotex Inc., and Aurobindo Pharma.

Bausch Health Companies Inc.: In March 2019, Bausch Health Companies Inc. announced that the Company has completed the acquisition of certain assets of Synergy Pharmaceuticals Inc. for a cash purchase price of approximately $195 million and the assumption of certain assumed liabilities, pursuant to the terms of the stalking horse asset purchase agreement previously entered into with Synergy and following approval by the U.S. Bankruptcy Court for the Southern District of New York

Mylan: In April 2020, the European Commission had approved, under the EU Merger Regulation, the proposed merger between the global pharmaceutical company Mylan and Upjohn, a business division of Pfizer, which operates Pfizer’s off-patent branded and generic established medicines. The decision is conditional on the divestment of Mylan’s business for certain generic medicines.

18. Lundbeck A/S: In October 2019, H. Lundbeck A/S announced that it had successfully completed the acquisition of Alder BioPharmaceuticals, Inc., a migraine-focused company based in Bothell, Washington. Lundbeck acquired Alder for an upfront payment of USD 18.00 per share, in cash, along with one non-tradeable Contingent Value Right (CVR) of USD 2.00 per share, payable – subject to certain terms and conditions – upon approval of eptinezumab by the European Medicines Agency (EMA), representing a total potential consideration of USD 20.00 per share.

Scope of the Report

By Product

• Alprazolam
• Lorazepam
• Diazepam
• Clonazepam
  

By Application

• Anxiety disorders
• Insomnia
• Seizures
• Alcohol Withdrawal

By Time of action

• Ultra-short Acting
• Short Acting
• Long Acting

By Region

• North America
• Europe
• Asia Pacific
• LAMEA

Key Reasons to Purchase this Report

1. It provides a technological development map over time to understand the growth rate of the industry.
2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
3. It renders definite analysis for changing competitive dynamics.
4. It builds a seven-year estimate based on how the market is predicted to grow.